P2X7 antagonist programme, EVT 401, to a top tier global animal health company partnered
Exclusive license granted to major animal health company for development of Evotec proprietary compound
Evotec is entitled to receive a technology- transfer payment, development and commercial milestone payments, and tiered royalties on net sales. Evotec retains all rights to the programme for human therapeutic use.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are very pleased to be partnering with a company that has proven capabilities for developing drug candidates for animal indications. This deal not only gives us additional product value, but also nicely proves the strength of our medicinal chemistry approach. We look forward to closely collaborate with this top animal health company to make this product development a success."
Financial details related to the agreement are not being disclosed.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.